MYELODYSPLASTIC SYNDROME TRANSFORMATION

This adverse event was reported 521 times

These drugs are most commonly taken by patients reporting MYELODYSPLASTIC SYNDROME TRANSFORMATION:

# Drug Count
0 LENALIDOMIDE 150
1 AZACITIDINE 129
2 DEFERASIROX 89
3 METHOTREXATE SODIUM 54
4 CYTARABINE 45
5 METHOTREXATE 45
6 TRETINOIN 29
7 ARSENIC TRIOXIDE 22
8 FUROSEMIDE 20
9 CYCLOPHOSPHAMIDE 19
See all common drugs associated with MYELODYSPLASTIC SYNDROME TRANSFORMATION

MYELODYSPLASTIC SYNDROME TRANSFORMATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 HELIOX 1 0.0256
1 PURIXAN 9 0.0116
2 ARSENIC TRIOXIDE 22 0.0095
3 LULICONAZOLE 1 0.0057
4 STREPTOZOCIN 1 0.0043
5 AZACITIDINE 129 0.0043
6 TRETINOIN 29 0.0035
7 DEFERASIROX 89 0.0034
8 TOREMIFENE CITRATE 1 0.0023
9 TALAZOPARIB 4 0.0022
See all drugs enriched for association with MYELODYSPLASTIC SYNDROME TRANSFORMATION

MYELODYSPLASTIC SYNDROME TRANSFORMATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Iron Chelator [EPC] 89 0.0030
1 Erythroid Maturation Agent [EPC] 2 0.0008
2 Nucleoside Metabolic Inhibitor [EPC] 179 0.0007
3 Actinomycin [EPC] 1 0.0005
4 Thrombopoietin Receptor Agonist [EPC] 6 0.0004
5 Poly(ADP-Ribose) Polymerase Inhibitor [EPC] 8 0.0004
6 Calcitonin [EPC] 1 0.0003
7 Interleukin-1 Receptor Antagonist [EPC] 5 0.0003
8 Thalidomide Analog [EPC] 152 0.0003
9 Penem Antibacterial [EPC] 8 0.0002
See all drug classes enriched for association with MYELODYSPLASTIC SYNDROME TRANSFORMATION